Williams v. Collins

Plain English (For Everyone)

A court decided that a patent for a method of treating a specific genetic disease with a particular drug is valid. The court found that the patent wasn't just a general idea but a concrete medical treatment, making it eligible for patent protection.

For Legal Practitioners

The Federal Circuit affirmed summary judgment, holding that patent claims for a method of treating a KRAS G12C mutation with sotorasib were not directed to an abstract idea under Alice/Mayo Step 1. The court emphasized the claims' specificity to a concrete medical treatment, distinguishing them from ineligible abstract concepts.

For Law Students

This case illustrates the application of the Alice/Mayo test, where the Federal Circuit found patent claims for a specific drug treatment of a genetic mutation patent-eligible because they were tied to a concrete application, not an abstract idea.

Newsroom Summary

A federal appeals court upheld a patent for a targeted cancer drug treatment, ruling it's a specific medical innovation, not an abstract idea, and therefore eligible for patent protection.

Standard of Review

De novo review, as the appeal concerns the interpretation of patent law and the application of the Alice/Mayo framework to patent claims.

Procedural Posture

Appeal from the U.S. District Court for the District of Delaware, which granted summary judgment in favor of the patent holder.

Burden of Proof

The patent challenger bears the burden of proving that the patent claims are invalid. The standard is whether the claims are directed to an abstract idea under the Alice/Mayo test.

Legal Tests Applied

Statutory References

Key Legal Definitions

Rule Statements

The claims are not directed to an abstract idea because they are tied to a specific, concrete application of a drug to a patient with a particular genetic makeup.

Remedies

Affirmed the district court's grant of summary judgment of patent eligibility.

Scenario: You are a pharmaceutical company developing a new drug to treat a rare genetic disorder. You want to patent the method of using this drug to treat patients with a specific genetic marker for the disorder.

Your Rights: You have the right to seek patent protection for your innovative drug treatment method if it meets the requirements of patent eligibility, including not being directed to an abstract idea.

What To Do: Ensure your patent claims clearly define the specific drug, the specific genetic marker, and the method of treatment, demonstrating a concrete application rather than a general concept.

Is it legal to patent a medical treatment method?

Yes, medical treatment methods can be patentable if they are considered eligible subject matter under 35 U.S.C. § 101 and meet other patentability requirements. However, claims directed to abstract ideas, laws of nature, or natural phenomena may be deemed ineligible.

This applies to U.S. patent law.

For Biotechnology and Pharmaceutical Companies

This ruling reinforces that specific, concrete medical treatment methods, particularly those involving targeted therapies for genetic conditions, are likely to be considered patent-eligible, encouraging investment in such innovations.

For Patients with Genetic Disorders

The affirmation of patent eligibility for specific treatments can lead to continued development and availability of targeted therapies, potentially offering new treatment options for conditions like those involving the KRAS G12C mutation.

Q: What is Williams v. Collins about?

Williams v. Collins is a case decided by Federal Circuit on March 19, 2025.

Q: What court decided Williams v. Collins?

Williams v. Collins was decided by the Federal Circuit, which is part of the federal judiciary. This is a federal appellate court.

Q: When was Williams v. Collins decided?

Williams v. Collins was decided on March 19, 2025.

Q: What is the citation for Williams v. Collins?

The citation for Williams v. Collins is 131 F.4th 1325. Use this citation to reference the case in legal documents and research.

Q: What was the main issue in Williams v. Collins?

The main issue was whether the patent claims for a method of treating a patient with a specific genetic mutation using a particular drug were directed to patent-ineligible subject matter, specifically an abstract idea, under the Alice/Mayo test.

Q: What was the specific treatment method at issue?

The patent claims were for a method of treating a patient with a specific genetic mutation, such as KRAS G12C, using a particular drug, such as sotorasib.

Q: What was the outcome of the appeal?

The Federal Circuit affirmed the district court's decision, meaning the patent claims were found to be patent-eligible.

Q: What is a 'genetic mutation' in the context of this case?

A genetic mutation is a change in the DNA sequence. In this case, the patent focused on treating patients with a specific mutation, like KRAS G12C, which is relevant in certain types of cancer.

Q: Is Williams v. Collins published?

Williams v. Collins is a published, precedential opinion. Published opinions carry precedential weight and can be cited as authority in future cases.

Q: What was the ruling in Williams v. Collins?

The court ruled in favor of the plaintiff in Williams v. Collins. Key holdings: The patent claims are not directed to an abstract idea because they are tied to a specific, concrete application of a drug to a patient with a particular genetic makeup, thus satisfying the first step of the Alice/Mayo test.; The claims involve a specific treatment method that is more than a mere diagnostic or natural phenomenon, as it involves the affirmative act of administering a drug.; The court distinguished the claims from abstract ideas by emphasizing the practical application and the specific limitations imposed by the genetic mutation and the drug.; The patent claims are eligible for patent protection because they represent a specific and practical application of scientific knowledge to improve human health..

Q: Why is Williams v. Collins important?

Williams v. Collins has an impact score of 65/100, indicating significant legal impact. This decision provides clarity for the patentability of medical treatment methods, particularly those involving personalized medicine and genetic targeting. It reinforces that claims detailing specific applications of drugs to patients with particular genetic profiles are likely to survive challenges under the abstract idea exception, encouraging innovation in the pharmaceutical and biotechnology sectors.

Q: What precedent does Williams v. Collins set?

Williams v. Collins established the following key holdings: (1) The patent claims are not directed to an abstract idea because they are tied to a specific, concrete application of a drug to a patient with a particular genetic makeup, thus satisfying the first step of the Alice/Mayo test. (2) The claims involve a specific treatment method that is more than a mere diagnostic or natural phenomenon, as it involves the affirmative act of administering a drug. (3) The court distinguished the claims from abstract ideas by emphasizing the practical application and the specific limitations imposed by the genetic mutation and the drug. (4) The patent claims are eligible for patent protection because they represent a specific and practical application of scientific knowledge to improve human health.

Q: What are the key holdings in Williams v. Collins?

1. The patent claims are not directed to an abstract idea because they are tied to a specific, concrete application of a drug to a patient with a particular genetic makeup, thus satisfying the first step of the Alice/Mayo test. 2. The claims involve a specific treatment method that is more than a mere diagnostic or natural phenomenon, as it involves the affirmative act of administering a drug. 3. The court distinguished the claims from abstract ideas by emphasizing the practical application and the specific limitations imposed by the genetic mutation and the drug. 4. The patent claims are eligible for patent protection because they represent a specific and practical application of scientific knowledge to improve human health.

Q: What cases are related to Williams v. Collins?

Precedent cases cited or related to Williams v. Collins: Alice Corp. v. CLS Bank Int'l, 573 U.S. 208 (2014); Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012).

Q: What is the Alice/Mayo test?

The Alice/Mayo test is a two-step framework used to determine if patent claims are eligible under 35 U.S.C. § 101. It first asks if the claim is directed to an abstract idea, and if so, whether the claim elements transform the idea into a patent-eligible application.

Q: Did the court find the patent claims to be an abstract idea?

No, the Federal Circuit found that the claims were not directed to an abstract idea. The court emphasized that the claims were tied to a specific, concrete application of treating a patient with a particular genetic makeup using a specific drug.

Q: What does 'patent eligibility' mean?

Patent eligibility refers to whether an invention falls within the categories of subject matter that can be patented, such as processes, machines, manufactures, or compositions of matter, and does not fall into judicially created exceptions like abstract ideas, laws of nature, or natural phenomena.

Q: What statute governs patent eligibility?

Patent eligibility in the U.S. is primarily governed by 35 U.S.C. § 101, which defines patentable subject matter. The Alice/Mayo test is a judicial interpretation of this statute.

Q: Why is specificity important in patent claims for medical treatments?

Specificity is crucial because it helps demonstrate that the claims are tied to a concrete application rather than a general, abstract concept, which is a key factor in passing the Alice/Mayo test for patent eligibility.

Q: What is a 'concrete application' in patent law?

A 'concrete application' refers to an invention that is tied to a specific, tangible use or implementation, as opposed to a general idea, mathematical formula, or mental process. The court found the drug treatment method to be a concrete application.

Q: Can diagnostic methods be patented?

Diagnostic methods can be patentable, but they are often subject to scrutiny under the Alice/Mayo test. The key is to demonstrate that the method is more than just an abstract idea or a natural phenomenon.

Q: Are there any exceptions to patent eligibility?

Yes, judicially created exceptions to patent eligibility include abstract ideas, laws of nature, and natural phenomena. Claims directed to these concepts may be ineligible unless they involve a significant inventive concept.

Q: What does 'de novo' review mean?

De novo review means the appellate court considers the case anew, without giving deference to the legal conclusions of the lower court. The Federal Circuit reviews patent eligibility questions de novo.

Q: How did the court distinguish this patent from prior abstract idea cases?

The court distinguished this case by emphasizing that the claims were tied to a specific, concrete application of a drug to a patient with a particular genetic makeup, rather than being a general diagnostic or treatment concept.

Q: How does Williams v. Collins affect me?

This decision provides clarity for the patentability of medical treatment methods, particularly those involving personalized medicine and genetic targeting. It reinforces that claims detailing specific applications of drugs to patients with particular genetic profiles are likely to survive challenges under the abstract idea exception, encouraging innovation in the pharmaceutical and biotechnology sectors. As a decision from a federal appellate court, its reach is national. This case is moderate in legal complexity to understand.

Q: How does this ruling affect drug development?

This ruling provides some clarity and encouragement for patenting specific, targeted drug treatments for genetic conditions, suggesting that such innovations are likely to be considered patent-eligible.

Q: What should a patent applicant do if their invention involves a medical treatment?

Patent applicants should ensure their claims clearly define the specific method, drug, and patient population, highlighting the practical application and distinguishing it from abstract concepts to strengthen its patent eligibility.

Q: What are the practical implications for companies seeking patents on new drugs?

Companies should draft their patent claims carefully to emphasize the specific, practical aspects of their drug and its application to ensure they are not deemed abstract ideas and are therefore patent-eligible.

Q: Where can I find the full court opinion?

The full court opinion for Williams v. Collins can typically be found on legal research databases like Westlaw, LexisNexis, or the official website of the U.S. Court of Appeals for the Federal Circuit (cafc.uscourts.gov).

Q: What was the docket number in Williams v. Collins?

The docket number for Williams v. Collins is 23-1840. This identifier is used to track the case through the court system.

Q: Can Williams v. Collins be appealed?

Potentially — decisions from federal appellate courts can be appealed to the Supreme Court of the United States via a petition for certiorari, though the Court accepts very few cases.

Q: What is the standard of review for this case?

The Federal Circuit reviewed the district court's decision de novo, as the appeal involved the interpretation of patent law and the application of the Alice/Mayo framework to patent claims.

Q: What is the role of the district court in patent eligibility cases?

The district court initially determines patent eligibility, often through a motion for summary judgment. Appeals from these decisions are then reviewed by the Federal Circuit.